Stocks
Arrowhead Pharmaceuticals (ARWR) EBITDA margin US GAAP (year values) |
||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | |||
| EBITDA margin, % | ? | -95.9% | -66.7% | -73.0% | -15 813% | 19.9% | -21.6% | |
| Changes by years, y/y, % | +3pp | +29pp | -6pp | -15 740pp | +15 833pp | |||
Arrowhead Pharmaceuticals. EBITDA margin, %
Arrowhead Pharmaceuticals. EBITDA margin, changes, pp
Arrowhead Pharmaceuticals (ARWR) EBITDA margin US GAAP (quarter values) |
||||||||
| FY2025Q3 | FY2025Q4 | FY2026Q1 | FY2026Q2 | FY2026Q3 | LTM ? | |||
| EBITDA margin, % | ? | -534.7% | 25.0% | 21.7% | -145.6% | -205.1% | -21.6% | |
| Changes by years, y/y, % | +5 951pp | -219pp | +330pp | |||||
| Changes by quarters, q/q, % | -608pp | +560pp | -3pp | -167pp | -60pp | |||
